Aurelia Nicoleta Cristea 1, B. S. Velescu 2
1 Profesor universitar, doctor în ştiinţe farmaceutice, Facultatea de Farmacie, UMF Carol Davila Bucureşti
2 Preparator universitar, doctorand, Facultatea de Farmacie, UMF Carol Davila Bucureşti
Abstract
Endogenous cannabinoid system (SCBE), classified as a lipidergic system, is relative recently discovered. Only in 1990, the first cannabinoid receptor CB1 has been cloned from cerebral tissue. The first endocannabinoid was identified from the porcine brain in 1992 (Devane et al.) as arachidonoylethanolamide (AEA) and named anandamida (from Sanskrit: ananda=joy, happiness, bliss, sensual pleasure). The effects of anandamide are mimed by delta 9-tetrahydrocannabinol (THC), identified in 1964 as the active phytocannabinoid responsible for the psychoactive effects of cannabis, resulting from the stimulation of the CB1 receptor type. This paper represents a review of the up-to-date knowledge about endogenous cannabinoid system (SCBE): history, receptors, mediators, catalyzing enzymatic systems of biosynthesis and metabolize, regulation and correlations with another signaling systems, physiological functions and pathological implications, as well as pharmacological perspectives. In a future paper the new drugs will be presented.